Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1078

1.

Characterization of Cerebrospinal Fluid BACE1 Species.

Lopez-Font I, Boix CP, Zetterberg H, Blennow K, Sáez-Valero J.

Mol Neurobiol. 2019 Jul 9. doi: 10.1007/s12035-019-01677-8. [Epub ahead of print]

PMID:
31290061
2.

IL-9 alterations linked to Alzheimer's disease in African Americans.

Wharton W, Kollhoff AL, Gangishetti U, Verble DD, Upadhya S, Zetterberg H, Kumar V, Watts KD, Kippels AJ, Gearing M, Howell JC, Parker MW, Hu WT.

Ann Neurol. 2019 Jul 4. doi: 10.1002/ana.25543. [Epub ahead of print]

PMID:
31271450
3.

Comparison of different MRI-based morphometric estimates for defining neurodegeneration across the Alzheimer's disease continuum.

Allison SL, Koscik RL, Cary RP, Jonaitis EM, Rowley HA, Chin NA, Zetterberg H, Blennow K, Carlsson CM, Asthana S, Bendlin BB, Johnson SC.

Neuroimage Clin. 2019 Jun 10;23:101895. doi: 10.1016/j.nicl.2019.101895. [Epub ahead of print]

4.

Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches.

Wilke C, Pujol-Calderón F, Barro C, Stransky E, Blennow K, Michalak Z, Deuschle C, Jeromin A, Zetterberg H, Schüle R, Höglund K, Kuhle J, Synofzik M.

Clin Chem Lab Med. 2019 May 9. pii: /j/cclm.ahead-of-print/cclm-2019-0015/cclm-2019-0015.xml. doi: 10.1515/cclm-2019-0015. [Epub ahead of print]

PMID:
31251725
5.

Evolution and clustering of prodromal parkinsonian features in GBA1 carriers.

Mullin S, Beavan M, Bestwick J, McNeill A, Proukakis C, Cox T, Hughes D, Mehta A, Zetterberg H, Schapira AHV.

Mov Disord. 2019 Jun 28. doi: 10.1002/mds.27775. [Epub ahead of print]

PMID:
31251436
6.

Sex Difference in CHI3L1 Expression Levels in Human Brain Aging and in Alzheimer's Disease.

Sanfilippo C, Castrogiovanni P, Imbesi R, Kazakowa M, Musumeci G, Blennow K, Zetterberg H, Di Rosa M.

Brain Res. 2019 Jun 24:146305. doi: 10.1016/j.brainres.2019.146305. [Epub ahead of print]

PMID:
31247206
7.

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status.

Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, Bittner T, Mattsson N, Eichenlaub U, Blennow K, Hansson O.

JAMA Neurol. 2019 Jun 24. doi: 10.1001/jamaneurol.2019.1632. [Epub ahead of print]

8.

SILK studies - capturing the turnover of proteins linked to neurodegenerative diseases.

Paterson RW, Gabelle A, Lucey BP, Barthélemy NR, Leckey CA, Hirtz C, Lehmann S, Sato C, Patterson BW, West T, Yarasheski K, Rohrer JD, Wildburger NC, Schott JM, Karch CM, Wray S, Miller TM, Elbert DL, Zetterberg H, Fox NC, Bateman RJ.

Nat Rev Neurol. 2019 Jul;15(7):419-427. doi: 10.1038/s41582-019-0222-0. Epub 2019 Jun 20. Review.

PMID:
31222062
9.

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.

Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE; and the NFL Group, Alvarez-Cermeño JC, Andreasson U, Axelsson M, Bäckström DC, Bartos A, Bjerke M, Blennow K, Boxer A, Brundin L, Burman J, Christensen T, Fialová L, Forsgren L, Frederiksen JL, Gisslén M, Gray E, Gunnarsson M, Hall S, Hansson O, Herbert MK, Jakobsson J, Jessen-Krut J, Janelidze S, Johannsson G, Jonsson M, Kappos L, Khademi M, Khalil M, Kuhle J, Landén M, Leinonen V, Logroscino G, Lu CH, Lycke J, Magdalinou NK, Malaspina A, Mattsson N, Meeter LH, Mehta SR, Modvig S, Olsson T, Paterson RW, Pérez-Santiago J, Piehl F, Pijnenburg YAL, Pyykkö OT, Ragnarsson O, Rojas JC, Romme Christensen J, Sandberg L, Scherling CS, Schott JM, Sellebjerg FT, Simone IL, Skillbäck T, Stilund M, Sundström P, Svenningsson A, Tortelli R, Tortorella C, Trentini A, Troiano M, Turner MR, van Swieten JC, Vågberg M, Verbeek MM, Villar LM, Visser PJ, Wallin A, Weiss A, Wikkelsø C, Wild EJ.

JAMA Neurol. 2019 Jun 17. doi: 10.1001/jamaneurol.2019.1534. [Epub ahead of print]

PMID:
31206160
10.

PDXK mutations cause polyneuropathy responsive to pyridoxal 5'-phosphate supplementation.

Chelban V, Wilson MP, Warman Chardon J, Vandrovcova J, Zanetti MN, Zamba-Papanicolaou E, Efthymiou S, Pope S, Conte MR, Abis G, Liu YT, Tribollet E, Haridy NA, Botía JA, Ryten M, Nicolaou P, Minaidou A, Christodoulou K, Kernohan KD, Eaton A, Osmond M, Ito Y, Bourque P, Jepson JEC, Bello O, Bremner F, Cordivari C, Reilly MM, Foiani M, Heslegrave A, Zetterberg H, Heales SJR, Wood NW, Rothman JE, Boycott KM, Mills PB, Clayton PT, Houlden H; Care4Rare Canada Consortium and the SYNaPS Study Group.

Ann Neurol. 2019 Aug;86(2):225-240. doi: 10.1002/ana.25524. Epub 2019 Jul 1.

PMID:
31187503
11.

Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures.

Mielke MM, Syrjanen JA, Blennow K, Zetterberg H, Vemuri P, Skoog I, Machulda MM, Kremers WK, Knopman DS, Jack C Jr, Petersen RC, Kern S.

Neurology. 2019 Jun 10. pii: 10.1212/WNL.0000000000007767. doi: 10.1212/WNL.0000000000007767. [Epub ahead of print]

PMID:
31182505
12.

Serum tau concentration after diving - an observational pilot study.

Rosén A, Oscarsson N, Kvarnström A, Gennser M, Sandström G, Blennow K, Seeman-Lodding H, Zetterberg H.

Diving Hyperb Med. 2019 Jun 30;49(2):88-95. doi: 10.28920/dhm49.2.88-95.

PMID:
31177514
13.

CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics.

Jeppsson A, Wikkelsö C, Blennow K, Zetterberg H, Constantinescu R, Remes AM, Herukka SK, Rauramaa T, Nagga K, Leinonen V, Tullberg M.

J Neurol Neurosurg Psychiatry. 2019 Jun 5. pii: jnnp-2019-320826. doi: 10.1136/jnnp-2019-320826. [Epub ahead of print]

14.

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype.

Vermunt L, Sikkes SAM, van den Hout A, Handels R, Bos I, van der Flier WM, Kern S, Ousset PJ, Maruff P, Skoog I, Verhey FRJ, Freund-Levi Y, Tsolaki M, Wallin ÅK, Olde Rikkert M, Soininen H, Spiru L, Zetterberg H, Blennow K, Scheltens P, Muniz-Terrera G, Visser PJ; Alzheimer Disease Neuroimaging Initiative; AIBL Research Group; ICTUS/DSA study groups.

Alzheimers Dement. 2019 Jun 1. pii: S1552-5260(19)30084-6. doi: 10.1016/j.jalz.2019.04.001. [Epub ahead of print]

PMID:
31164314
15.

Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer's Disease.

Minta K, Portelius E, Janelidze S, Hansson O, Zetterberg H, Blennow K, Andreasson U.

J Alzheimers Dis. 2019;69(4):1213-1220. doi: 10.3233/JAD-190187.

PMID:
31156172
16.

Serum Neurofilament Light Chain Concentration Correlates with Infarct Volume but Not Prognosis in Acute Ischemic Stroke.

Onatsu J, Vanninen R, Jäkälä P, Mustonen P, Pulkki K, Korhonen M, Hedman M, Zetterberg H, Blennow K, Höglund K, Herukka SK, Taina M.

J Stroke Cerebrovasc Dis. 2019 May 28. pii: S1052-3057(19)30228-9. doi: 10.1016/j.jstrokecerebrovasdis.2019.05.008. [Epub ahead of print]

PMID:
31151840
17.

Disease signatures: Biomarkers/indicators of neurodegeneration.

Zetterberg H, Bähr M.

Mol Cell Neurosci. 2019 Jun;97:1-2. doi: 10.1016/j.mcn.2019.05.004. Epub 2019 May 25. No abstract available.

PMID:
31132397
18.

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity.

van der Lee SJ, Conway OJ, Jansen I, Carrasquillo MM, Kleineidam L, van den Akker E, Hernández I, van Eijk KR, Stringa N, Chen JA, Zettergren A, Andlauer TFM, Diez-Fairen M, Simon-Sanchez J, Lleó A, Zetterberg H, Nygaard M, Blauwendraat C, Savage JE, Mengel-From J, Moreno-Grau S, Wagner M, Fortea J, Keogh MJ, Blennow K, Skoog I, Friese MA, Pletnikova O, Zulaica M, Lage C, de Rojas I, Riedel-Heller S, Illán-Gala I, Wei W, Jeune B, Orellana A, Then Bergh F, Wang X, Hulsman M, Beker N, Tesi N, Morris CM, Indakoetxea B, Collij LE, Scherer M, Morenas-Rodríguez E, Ironside JW, van Berckel BNM, Alcolea D, Wiendl H, Strickland SL, Pastor P, Rodríguez Rodríguez E; DESGESCO (Dementia Genetics Spanish Consortium), EADB (Alzheimer Disease European DNA biobank); EADB (Alzheimer Disease European DNA biobank); IFGC (International FTD-Genomics Consortium), IPDGC (The International Parkinson Disease Genomics Consortium); IPDGC (The International Parkinson Disease Genomics Consortium); RiMod-FTD (Risk and Modifying factors in Fronto-Temporal Dementia); Netherlands Brain Bank (NBB), Boeve BF, Petersen RC, Ferman TJ, van Gerpen JA, Reinders MJT, Uitti RJ, Tárraga L, Maier W, Dols-Icardo O, Kawalia A, Dalmasso MC, Boada M, Zettl UK, van Schoor NM, Beekman M, Allen M, Masliah E, de Munain AL, Pantelyat A, Wszolek ZK, Ross OA, Dickson DW, Graff-Radford NR, Knopman D, Rademakers R, Lemstra AW, Pijnenburg YAL, Scheltens P, Gasser T, Chinnery PF, Hemmer B, Huisman MA, Troncoso J, Moreno F, Nohr EA, Sørensen TIA, Heutink P, Sánchez-Juan P, Posthuma D; GIFT (Genetic Investigation in Frontotemporal Dementia and Alzheimer’s Disease) Study Group, Clarimón J, Christensen K, Ertekin-Taner N, Scholz SW, Ramirez A, Ruiz A, Slagboom E, van der Flier WM, Holstege H.

Acta Neuropathol. 2019 May 27. doi: 10.1007/s00401-019-02026-8. [Epub ahead of print]

PMID:
31131421
19.

Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis.

Gaetani L, Salvadori N, Lisetti V, Eusebi P, Mancini A, Gentili L, Borrelli A, Portaccio E, Sarchielli P, Blennow K, Zetterberg H, Parnetti L, Calabresi P, Di Filippo M.

J Neurol. 2019 May 25. doi: 10.1007/s00415-019-09398-7. [Epub ahead of print]

PMID:
31129709
20.

Longstanding psychological stress in relation to biomarkers of neuronal dysfunction in cerebrospinal fluid: a 25-year follow-up study in women.

Johansson L, Sacuiu S, Kern S, Guo X, Zetterberg H, Blennow K, Zettergren A, Skoog I.

Neurobiol Aging. 2019 Feb 27;80:111-115. doi: 10.1016/j.neurobiolaging.2019.02.013. [Epub ahead of print]

PMID:
31128566
21.

NFL is a marker of treatment response in children with SMA treated with nusinersen.

Olsson B, Alberg L, Cullen NC, Michael E, Wahlgren L, Kroksmark AK, Rostasy K, Blennow K, Zetterberg H, Tulinius M.

J Neurol. 2019 May 23. doi: 10.1007/s00415-019-09389-8. [Epub ahead of print]

PMID:
31123861
22.

Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease.

Vergallo A, Mégret L, Lista S, Cavedo E, Zetterberg H, Blennow K, Vanmechelen E, De Vos A, Habert MO, Potier MC, Dubois B, Neri C, Hampel H; INSIGHT-preAD study group; Alzheimer Precision Medicine Initiative (APMI).

Alzheimers Dement. 2019 Jun;15(6):764-775. doi: 10.1016/j.jalz.2019.03.009. Epub 2019 May 18.

PMID:
31113759
23.

Erlangen Score Predicts Cognitive and Neuroimaging Progression in Mild Cognitive Impairment Stage of Alzheimer's Disease.

Skillbäck T, Kornhuber J, Blennow K, Zetterberg H, Lewczuk P; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2019;69(2):551-559. doi: 10.3233/JAD-190067.

PMID:
31104027
24.

Reduced vascular endothelial growth factor levels in the cerebrospinal fluid in patients with treatment resistant major depression and the effects of electroconvulsive therapy-A pilot study.

Kranaster L, Blennow K, Zetterberg H, Sartorius A.

J Affect Disord. 2019 Jun 15;253:449-453. doi: 10.1016/j.jad.2019.04.080. Epub 2019 Apr 18.

PMID:
31103810
25.

CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD.

Blennow K, Diaz-Lucena D, Zetterberg H, Villar-Pique A, Karch A, Vidal E, Hermann P, Schmitz M, Ferrer Abizanda I, Zerr I, Llorens F.

J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):846-853. doi: 10.1136/jnnp-2018-320155. Epub 2019 May 16.

PMID:
31097472
26.

Head trauma in sports and risk for dementia.

Winblad B, Ankarcrona M, Johansson G, Novak P, Peter Thelin E, Zetterberg H, Blennow K.

J Intern Med. 2019 Jun;285(6):591-593. doi: 10.1111/joim.12918. Epub 2019 May 15. No abstract available.

PMID:
31090251
27.

Breaking the cycle: Reversal of flux in the tricarboxylic acid cycle by dimethyl fumarate.

Gafson AR, Savva C, Thorne T, David M, Gomez-Romero M, Lewis MR, Nicholas R, Heslegrave A, Zetterberg H, Matthews PM.

Neurol Neuroimmunol Neuroinflamm. 2019 Apr 22;6(3):e562. doi: 10.1212/NXI.0000000000000562. eCollection 2019 May.

28.

CSF Beta-amyloid 1-42 Concentration Predicts Delirium Following Elective Arthroplasty Surgery in an Observational Cohort Study.

Cunningham EL, McGuinness B, McAuley DF, Toombs J, Mawhinney T, O'Brien S, Beverland D, Schott JM, Lunn MP, Zetterberg H, Passmore AP.

Ann Surg. 2019 Jun;269(6):1200-1205. doi: 10.1097/SLA.0000000000002684.

PMID:
31082921
29.

Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort.

Kim M, Snowden S, Suvitaival T, Ali A, Merkler DJ, Ahmad T, Westwood S, Baird A, Proitsi P, Nevado-Holgado A, Hye A, Bos I, Vos S, Vandenberghe R, Teunissen C, Ten Kate M, Scheltens P, Gabel S, Meersmans K, Blin O, Richardson J, De Roeck E, Sleegers K, Bordet R, Rami L, Kettunen P, Tsolaki M, Verhey F, Sala I, Lléo A, Peyratout G, Tainta M, Johannsen P, Freund-Levi Y, Frölich L, Dobricic V, Engelborghs S, Frisoni GB, Molinuevo JL, Wallin A, Popp J, Martinez-Lage P, Bertram L, Barkhof F, Ashton N, Blennow K, Zetterberg H, Streffer J, Visser PJ, Lovestone S, Legido-Quigley C.

Alzheimers Dement. 2019 Jun;15(6):817-827. doi: 10.1016/j.jalz.2019.03.004. Epub 2019 May 8.

30.

A Serum Protein Biomarker Panel Improves Outcome Prediction in Human Traumatic Brain Injury.

Thelin E, Al Nimer F, Frostell A, Zetterberg H, Blennow K, Nyström H, Svensson M, Bellander BM, Piehl F, Nelson DW.

J Neurotrauma. 2019 Jun 19. doi: 10.1089/neu.2019.6375. [Epub ahead of print]

PMID:
31072225
31.

Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report.

Bateman RJ, Blennow K, Doody R, Hendrix S, Lovestone S, Salloway S, Schindler R, Weiner M, Zetterberg H, Aisen P, Vellas B.

J Prev Alzheimers Dis. 2019;6(3):169-173. doi: 10.14283/jpad.2019.21.

PMID:
31062827
32.

Association of Blood and Cerebrospinal Fluid Tau Level and Other Biomarkers With Survival Time in Sporadic Creutzfeldt-Jakob Disease.

Staffaroni AM, Kramer AO, Casey M, Kang H, Rojas JC, Orrú CD, Caughey B, Allen IE, Kramer JH, Rosen HJ, Blennow K, Zetterberg H, Geschwind MD.

JAMA Neurol. 2019 May 6. doi: 10.1001/jamaneurol.2019.1071. [Epub ahead of print]

PMID:
31058916
33.

Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease.

Timmers M, Tesseur I, Bogert J, Zetterberg H, Blennow K, Börjesson-Hanson A, Baquero M, Boada M, Randolph C, Tritsmans L, Van Nueten L, Engelborghs S, Streffer JR.

Neurobiol Aging. 2019 Jul;79:131-141. doi: 10.1016/j.neurobiolaging.2019.03.016. Epub 2019 Apr 1.

PMID:
31055223
34.

Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid-β and tau.

Jacobs KR, Lim CK, Blennow K, Zetterberg H, Chatterjee P, Martins RN, Brew BJ, Guillemin GJ, Lovejoy DB.

Neurobiol Aging. 2019 Apr 1;80:11-20. doi: 10.1016/j.neurobiolaging.2019.03.015. [Epub ahead of print]

PMID:
31055163
35.

Inflammatory biomarkers in Alzheimer's disease plasma.

Morgan AR, Touchard S, Leckey C, O'Hagan C, Nevado-Holgado AJ; NIMA Consortium, Barkhof F, Bertram L, Blin O, Bos I, Dobricic V, Engelborghs S, Frisoni G, Frölich L, Gabel S, Johannsen P, Kettunen P, Kłoszewska I, Legido-Quigley C, Lleó A, Martinez-Lage P, Mecocci P, Meersmans K, Molinuevo JL, Peyratout G, Popp J, Richardson J, Sala I, Scheltens P, Streffer J, Soininen H, Tainta-Cuezva M, Teunissen C, Tsolaki M, Vandenberghe R, Visser PJ, Vos S, Wahlund LO, Wallin A, Westwood S, Zetterberg H, Lovestone S, Morgan BP; Annex: NIMA–Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer's Disease.

Alzheimers Dement. 2019 Jun;15(6):776-787. doi: 10.1016/j.jalz.2019.03.007. Epub 2019 Apr 30.

36.

Identification of neurotoxic cross-linked amyloid-β dimers in the Alzheimer's brain.

Brinkmalm G, Hong W, Wang Z, Liu W, O'Malley TT, Sun X, Frosch MP, Selkoe DJ, Portelius E, Zetterberg H, Blennow K, Walsh DM.

Brain. 2019 May 1;142(5):1441-1457. doi: 10.1093/brain/awz066.

PMID:
31032851
37.

The Cerebrospinal Fluid in Multiple Sclerosis.

Deisenhammer F, Zetterberg H, Fitzner B, Zettl UK.

Front Immunol. 2019 Apr 12;10:726. doi: 10.3389/fimmu.2019.00726. eCollection 2019. Review.

38.

Serum tau fragments as predictors of death or poor neurological outcome after out-of-hospital cardiac arrest.

Grand J, Kjaergaard J, Nielsen N, Friberg H, Cronberg T, Bro-Jeppesen J, Karsdal MA, Nielsen HB, Frydland M, Henriksen K, Mattsson N, Zetterberg H, Hassager C.

Biomarkers. 2019 May 31:1-8. doi: 10.1080/1354750X.2019.1609580. [Epub ahead of print]

PMID:
31017476
39.

Differential effects of neurodegeneration biomarkers on subclinical cognitive decline.

Merluzzi AP, Vogt NM, Norton D, Jonaitis E, Clark LR, Carlsson CM, Johnson SC, Asthana S, Blennow K, Zetterberg H, Bendlin BB.

Alzheimers Dement (N Y). 2019 Apr 12;5:129-138. doi: 10.1016/j.trci.2019.02.004. eCollection 2019.

40.

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease.

Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P.

Alzheimers Res Ther. 2019 Apr 22;11(1):34. doi: 10.1186/s13195-019-0485-0. Review.

41.

Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.

Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K.

JAMA Neurol. 2019 Apr 22. doi: 10.1001/jamaneurol.2019.0765. [Epub ahead of print] Erratum in: JAMA Neurol. 2019 Jun 10;:.

PMID:
31009028
42.

Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest.

Foiani MS, Cicognola C, Ermann N, Woollacott IOC, Heller C, Heslegrave AJ, Keshavan A, Paterson RW, Ye K, Kornhuber J, Fox NC, Schott JM, Warren JD, Lewczuk P, Zetterberg H, Blennow K, Höglund K, Rohrer JD.

J Neurol Neurosurg Psychiatry. 2019 Jul;90(7):740-746. doi: 10.1136/jnnp-2018-319266. Epub 2019 Apr 13.

43.

Exercise as a potential modulator of inflammation in patients with Alzheimer's disease measured in cerebrospinal fluid and plasma.

Jensen CS, Bahl JM, Østergaard LB, Høgh P, Wermuth L, Heslegrave A, Zetterberg H, Heegaard NHH, Hasselbalch SG, Simonsen AH.

Exp Gerontol. 2019 Jul 1;121:91-98. doi: 10.1016/j.exger.2019.04.003. Epub 2019 Apr 11.

44.

Dynamics of extracellular matrix proteins in cerebrospinal fluid and serum and their relation to clinical outcome in human traumatic brain injury.

Minta K, Cullen NC, Nimer FA, Thelin EP, Piehl F, Clarin M, Tullberg M, Jeppsson A, Portelius E, Zetterberg H, Blennow K, Andreasson U.

Clin Chem Lab Med. 2019 Apr 15. pii: /j/cclm.ahead-of-print/cclm-2019-0034/cclm-2019-0034.xml. doi: 10.1515/cclm-2019-0034. [Epub ahead of print]

PMID:
30980710
45.

Familial Alzheimer's disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta.

Arber C, Toombs J, Lovejoy C, Ryan NS, Paterson RW, Willumsen N, Gkanatsiou E, Portelius E, Blennow K, Heslegrave A, Schott JM, Hardy J, Lashley T, Fox NC, Zetterberg H, Wray S.

Mol Psychiatry. 2019 Apr 12. doi: 10.1038/s41380-019-0410-8. [Epub ahead of print]

PMID:
30980041
46.

Amyloid β42 and Total Tau Levels in Cerebrospinal Fluid Associate with Survival in an 85-Year-Old Population-Based Cohort Followed until Death.

Ribbe M, Kern S, Börjesson Hansson A, Östling S, Zetterberg H, Blennow K, Skoog I.

Dement Geriatr Cogn Disord. 2019;47(1-2):114-124. doi: 10.1159/000499066. Epub 2019 Apr 10.

PMID:
30970371
47.

Neurofilament light chain as a biomarker in neurological disorders.

Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H.

J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):870-881. doi: 10.1136/jnnp-2018-320106. Epub 2019 Apr 9. Review.

PMID:
30967444
48.

Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.

Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER, Tainta M, Izaguirre A, Reijs BLR, Farotti L, Tsolaki M, Vandenbergue R, Freund-Levi Y, Verhey FRJ, Clarimón J, Fortea J, Frolich L, Santana I, Molinuevo JL, Lehmann S, Visser PJ, Teunissen CE, Zetterberg H, Blennow K.

Alzheimers Dement. 2019 Jun;15(6):742-753. doi: 10.1016/j.jalz.2019.01.015. Epub 2019 Apr 6.

PMID:
30967340
49.

Cardiorespiratory Fitness Modifies Influence of Sleep Problems on Cerebrospinal Fluid Biomarkers in an At-Risk Cohort.

Law LL, Sprecher KE, Dougherty RJ, Edwards DF, Koscik RL, Gallagher CL, Carlsson CM, Zetterberg H, Blennow K, Asthana S, Sager MA, Hermann BP, Johnson SC, Cook DB, Bendlin BB, Okonkwo OC.

J Alzheimers Dis. 2019;69(1):111-121. doi: 10.3233/JAD-180291.

PMID:
30958346
50.

Sleep deprivation and plasma biomarkers for Alzheimer's disease.

Olsson M, Ärlig J, Hedner J, Blennow K, Zetterberg H.

Sleep Med. 2019 May;57:92-93. doi: 10.1016/j.sleep.2018.12.029. Epub 2019 Feb 12. No abstract available.

PMID:
30953929

Supplemental Content

Loading ...
Support Center